首页 > 最新文献

Neuropharmacology最新文献

英文 中文
The frequency of binge-like ethanol exposure bidirectionally regulates hippocampal mGlu-LTD via synaptic mechanisms and this effect is reversed by minocycline 酗酒样乙醇暴露的频率通过突触机制双向调节海马mGlu-LTD,这种作用被米诺环素逆转
IF 4.6 2区 医学 Q1 NEUROSCIENCES Pub Date : 2026-01-14 DOI: 10.1016/j.neuropharm.2026.110836
M. Debris , C. Deschamps , M. Martin , L. Zabijak , M. Ouriemi , M. Ropiquet , C. Vilpoux , M. Naassila , O. Pierrefiche
Alcohol addiction may begin in young adults through binge drinking (BD) with its frequency as key criterion. In rodents, BD impairs memory and hippocampal synaptic plasticity on the short term and induced neuroinflammation. Memory impairments may persist into adulthood, whereas long-lasting disturbances in hippocampus synaptic plasticity have not been documented. Moreover, the impact of BD frequency on such disturbances and the potential of anti-inflammatory agents to reverse BD-induced alterations remain unclear. Using hippocampal slices from male rats subjected to eight binge-like episodes delivered at high (HF) or low (LF) frequency during adolescence, we found that alterations in group I metabotropic long-term depression (mGlu1/5-LTD) were related to binge-like exposure frequency, with HF reducing mGlu1/5-LTD and intriguingly, LF increasing it. Inhibiting mTORC1 with rapamycin partially corrected LF and HF effects, without alteration of ribosomal protein S6 phosphorylation, a protein downstream of mTORC1, after LF and, a decrease of rp-S6235/236 after HF. Moreover, LF decreased presynaptic GABA vesicular transporter and bicuculline replicated the increased mGlu1/5-LTD after LF. Additionally, N-methyl-D-aspartate receptor-dependent LTD was transiently reduced after HF or LF and rescued with a GluN2B antagonist. Finally, the anti-inflammatory agent, minocycline, administered after the ethanol exposure, reversed all synaptic plasticity alterations. We concluded that bidirectional alteration in mGlu1/5-LTD is a hallmark of ethanol binge exposure frequency, involving pre- and postsynaptic mechanisms. Targeting GluN2B and using anti-inflammatory agents offers promising therapeutic strategies to mitigate the synaptic effects of BD. Our findings highlight the frequency of ethanol exposure as a key determinant of neuronal impact.
酒精成瘾可能始于年轻人的酗酒(BD),其频率是关键标准。在啮齿类动物中,双相障碍在短期内损害记忆和海马突触可塑性并诱发神经炎症。记忆障碍可能会持续到成年,而海马体突触可塑性的长期紊乱尚未被证实。此外,BD频率对这种紊乱的影响以及抗炎药逆转BD诱导的改变的潜力仍不清楚。通过对青春期经历8次高(HF)或低(LF)频率暴饮暴食样发作的雄性大鼠的海马切片,我们发现I组代谢性长期抑郁(mGlu1/5-LTD)的变化与暴饮暴食样暴露频率有关,HF降低了mGlu1/5-LTD,有趣的是,LF增加了mGlu1/5-LTD。用雷帕霉素抑制mTORC1部分纠正了LF和HF的作用,而不改变LF后mTORC1下游蛋白S6的核糖体磷酸化,HF后rp-S6235/236的降低。此外,LF降低了突触前GABA囊泡转运蛋白,双球茎碱复制了LF后增加的mGlu1/5-LTD。此外,n -甲基-d -天冬氨酸受体依赖性LTD在HF或LF后短暂降低,并使用GluN2B拮抗剂进行挽救。最后,在乙醇暴露后给予抗炎剂二甲胺四环素,逆转了所有突触可塑性的改变。我们得出结论,mGlu1/5-LTD的双向改变是乙醇暴暴露频率的标志,涉及突触前和突触后机制。靶向GluN2B并使用抗炎药物为减轻双相障碍的突触效应提供了有希望的治疗策略。我们的研究结果强调了乙醇暴露频率是神经元影响的关键决定因素。
{"title":"The frequency of binge-like ethanol exposure bidirectionally regulates hippocampal mGlu-LTD via synaptic mechanisms and this effect is reversed by minocycline","authors":"M. Debris ,&nbsp;C. Deschamps ,&nbsp;M. Martin ,&nbsp;L. Zabijak ,&nbsp;M. Ouriemi ,&nbsp;M. Ropiquet ,&nbsp;C. Vilpoux ,&nbsp;M. Naassila ,&nbsp;O. Pierrefiche","doi":"10.1016/j.neuropharm.2026.110836","DOIUrl":"10.1016/j.neuropharm.2026.110836","url":null,"abstract":"<div><div>Alcohol addiction may begin in young adults through binge drinking (BD) with its frequency as key criterion. In rodents, BD impairs memory and hippocampal synaptic plasticity on the short term and induced neuroinflammation. Memory impairments may persist into adulthood, whereas long-lasting disturbances in hippocampus synaptic plasticity have not been documented. Moreover, the impact of BD frequency on such disturbances and the potential of anti-inflammatory agents to reverse BD-induced alterations remain unclear. Using hippocampal slices from male rats subjected to eight binge-like episodes delivered at high (HF) or low (LF) frequency during adolescence, we found that alterations in group I metabotropic long-term depression (mGlu<sub>1/5</sub>-LTD) were related to binge-like exposure frequency, with HF reducing mGlu<sub>1/5</sub>-LTD and intriguingly, LF increasing it. Inhibiting mTORC1 with rapamycin partially corrected LF and HF effects, without alteration of ribosomal protein S6 phosphorylation, a protein downstream of mTORC1, after LF and, a decrease of rp-S6<sup>235/236</sup> after HF. Moreover, LF decreased presynaptic GABA vesicular transporter and bicuculline replicated the increased mGlu<sub>1/5</sub>-LTD after LF. Additionally, <em>N</em>-methyl-D-aspartate receptor-dependent LTD was transiently reduced after HF or LF and rescued with a GluN2B antagonist. Finally, the anti-inflammatory agent, minocycline, administered after the ethanol exposure, reversed all synaptic plasticity alterations. We concluded that bidirectional alteration in mGlu<sub>1/5</sub>-LTD is a hallmark of ethanol binge exposure frequency, involving pre- and postsynaptic mechanisms. Targeting GluN2B and using anti-inflammatory agents offers promising therapeutic strategies to mitigate the synaptic effects of BD. Our findings highlight the frequency of ethanol exposure as a key determinant of neuronal impact.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"287 ","pages":"Article 110836"},"PeriodicalIF":4.6,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145979710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Electrocorticographic, Astrocytic and Transcriptomic Signatures in the Triple Transgenic Mouse Model of Alzheimer's Disease submitted to Stearoyl-CoA Desaturase Inhibition. 硬脂酰辅酶a去饱和酶抑制下阿尔茨海默病三重转基因小鼠模型的皮质电图、星形细胞和转录组特征
IF 4.6 2区 医学 Q1 NEUROSCIENCES Pub Date : 2026-01-13 DOI: 10.1016/j.neuropharm.2026.110835
Audrey Hector, Tanya Leduc, Maria João da Costa Caiado, Benoît Delignat-Lavaud, Julien Dufort-Gervais, Caroline Daneault, Christine Des Rosiers, Clément Bourguignon, Jean-Marc Lina, Karl Fernandes, Jonathan Brouillette, Valérie Mongrain

Alzheimer's disease (AD) is associated with cognitive deficits and sleep disturbances. Research suggests the involvement of dysfunctions in lipid metabolism in the brain of AD patients and animal models. The inhibition of stearoyl-CoA desaturase (SCD), a lipid-converting enzyme, was shown to restore memory in triple transgenic (3xTg)-AD mice. In the brain, astrocytes regulate the synthesis of specific lipids. This project tested whether the inhibition of SCD restores sleep in 3xTg-AD mice, and whether this associates with modifications in lipids, astrocytic function and the transcriptome. Wild-type (WT) and 3xTg-AD female mice received a SCD inhibitor (SCDi) or vehicle, which was followed by an electrocorticographic (ECoG) recording. Brain slices were stained for lipid droplets, astrocytic markers or processed for spatial transcriptomics. The reduced time spent awake (increased time spent in slow wave sleep) in 3xTg-AD mice was not restored by SCDi treatment. Rhythmic and scale-free ECoG activities were markedly altered in 3xTg-AD mice for all wake/sleep states, and SCDi changed these ECoG signatures differently in mutant in comparison to WT mice. GFAP-positive cell density and lipid droplet count were elevated in hippocampal CA1, and rescued by SCDi. The treatment also rescued the expression of several genes in a manner mainly overlapping between brain regions. The findings suggest that the multiple wake/sleep alterations in 3xTg-AD mice are not mitigated by SCD inhibition, but that this treatment can revert changes in hippocampal astrocytes, lipids and in the brain transcriptome. This work will benefit the understanding of the AD pathophysiology and associated sleep disturbances.

阿尔茨海默病(AD)与认知缺陷和睡眠障碍有关。研究表明,AD患者和动物模型的脑脂质代谢功能障碍参与其中。脂质转化酶硬脂酰辅酶a去饱和酶(SCD)的抑制被证明可以恢复三重转基因(3xTg)-AD小鼠的记忆。在大脑中,星形胶质细胞调节特定脂质的合成。该项目测试了SCD的抑制是否能恢复3xTg-AD小鼠的睡眠,以及这是否与脂质、星形细胞功能和转录组的改变有关。野生型(WT)和3xTg-AD雌性小鼠接受SCD抑制剂(SCDi)或载药,随后进行皮质电图(ECoG)记录。对脑切片进行脂滴、星形细胞标记物染色或空间转录组学处理。3xTg-AD小鼠清醒时间的减少(慢波睡眠时间的增加)未被SCDi治疗恢复。在3xTg-AD小鼠的所有清醒/睡眠状态下,节律性和无标度ECoG活动都显著改变,与WT小鼠相比,SCDi在突变体中改变了这些ECoG特征。海马CA1中gfap阳性细胞密度和脂滴计数升高,并被SCDi挽救。这种治疗还以一种主要在大脑区域之间重叠的方式挽救了几个基因的表达。研究结果表明,3xTg-AD小鼠的多重觉醒/睡眠改变不会因SCD抑制而减轻,但这种治疗可以恢复海马星形胶质细胞、脂质和脑转录组的变化。这项工作将有助于了解阿尔茨海默病的病理生理和相关的睡眠障碍。
{"title":"Electrocorticographic, Astrocytic and Transcriptomic Signatures in the Triple Transgenic Mouse Model of Alzheimer's Disease submitted to Stearoyl-CoA Desaturase Inhibition.","authors":"Audrey Hector, Tanya Leduc, Maria João da Costa Caiado, Benoît Delignat-Lavaud, Julien Dufort-Gervais, Caroline Daneault, Christine Des Rosiers, Clément Bourguignon, Jean-Marc Lina, Karl Fernandes, Jonathan Brouillette, Valérie Mongrain","doi":"10.1016/j.neuropharm.2026.110835","DOIUrl":"https://doi.org/10.1016/j.neuropharm.2026.110835","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is associated with cognitive deficits and sleep disturbances. Research suggests the involvement of dysfunctions in lipid metabolism in the brain of AD patients and animal models. The inhibition of stearoyl-CoA desaturase (SCD), a lipid-converting enzyme, was shown to restore memory in triple transgenic (3xTg)-AD mice. In the brain, astrocytes regulate the synthesis of specific lipids. This project tested whether the inhibition of SCD restores sleep in 3xTg-AD mice, and whether this associates with modifications in lipids, astrocytic function and the transcriptome. Wild-type (WT) and 3xTg-AD female mice received a SCD inhibitor (SCDi) or vehicle, which was followed by an electrocorticographic (ECoG) recording. Brain slices were stained for lipid droplets, astrocytic markers or processed for spatial transcriptomics. The reduced time spent awake (increased time spent in slow wave sleep) in 3xTg-AD mice was not restored by SCDi treatment. Rhythmic and scale-free ECoG activities were markedly altered in 3xTg-AD mice for all wake/sleep states, and SCDi changed these ECoG signatures differently in mutant in comparison to WT mice. GFAP-positive cell density and lipid droplet count were elevated in hippocampal CA1, and rescued by SCDi. The treatment also rescued the expression of several genes in a manner mainly overlapping between brain regions. The findings suggest that the multiple wake/sleep alterations in 3xTg-AD mice are not mitigated by SCD inhibition, but that this treatment can revert changes in hippocampal astrocytes, lipids and in the brain transcriptome. This work will benefit the understanding of the AD pathophysiology and associated sleep disturbances.</p>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":" ","pages":"110835"},"PeriodicalIF":4.6,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145990184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lactate-driven H3K27 lactylation promotes Olig2-dependent remyelination and motor recovery after spinal cord injury 乳酸驱动的H3K27乳酸化促进脊髓损伤后寡糖依赖的髓鞘再生和运动恢复。
IF 4.6 2区 医学 Q1 NEUROSCIENCES Pub Date : 2026-01-10 DOI: 10.1016/j.neuropharm.2026.110832
Zongxin Zhu , Ximiao Chen , Hanwen Zhang , Ronghui Miao , Huiling Yu , Shiying Zhao , Youli Zhang , Tanxin Yu , Di Zhang , Yifei Zhou , Xiaolei Zhang , Wei Zhang
Demyelination caused by oligodendrocyte death is a key contributor to neurological deficits after spinal cord injury (SCI), highlighting the critical need to promote oligodendrocyte precursor cell (OPC) differentiation and remyelination. The transcription factor Olig2 is a master regulator of this process; however, its activation mechanism remains unclear. Given the marked lactate accumulation in post-SCI ischemic microenvironments, we investigated the role of lactate in SCI as well as its regulation on OPC differentiation. In a rat SCI model, it is found that exogenous lactate administration significantly improves motor recovery, preserves neurons and axons, modulates the glial response. Mechanistically, lactate induces histone H3K27 lactylation (H3K27la), which specifically upregulates Olig2 expression, thereby activating OPC differentiation and remyelination. This study uncovers the lactate-H3K27la-Olig2 metabolic-epigenetic axis as a novel endogenous repair mechanism for SCI, providing a foundation for metabolism-targeted therapeutic strategies.
少突胶质细胞死亡导致的脱髓鞘是脊髓损伤(SCI)后神经功能缺损的一个关键因素,因此迫切需要促进少突胶质前体细胞(OPC)分化和髓鞘再生。转录因子Olig2是这一过程的主要调控因子;然而,其激活机制尚不清楚。鉴于脊髓损伤后缺血微环境中乳酸的显著积累,我们研究了乳酸在脊髓损伤中的作用及其对OPC分化的调控。在大鼠脊髓损伤模型中,外源性乳酸可显著改善运动恢复,保护神经元和轴突,调节神经胶质反应。在机制上,乳酸诱导组蛋白H3K27乳酸化(H3K27la),特异性上调Olig2表达,从而激活OPC分化和髓鞘再生。本研究揭示了乳酸- h3k27la - olig2代谢-表观遗传轴作为一种新的内源性损伤修复机制,为制定代谢靶向治疗策略提供了基础。
{"title":"Lactate-driven H3K27 lactylation promotes Olig2-dependent remyelination and motor recovery after spinal cord injury","authors":"Zongxin Zhu ,&nbsp;Ximiao Chen ,&nbsp;Hanwen Zhang ,&nbsp;Ronghui Miao ,&nbsp;Huiling Yu ,&nbsp;Shiying Zhao ,&nbsp;Youli Zhang ,&nbsp;Tanxin Yu ,&nbsp;Di Zhang ,&nbsp;Yifei Zhou ,&nbsp;Xiaolei Zhang ,&nbsp;Wei Zhang","doi":"10.1016/j.neuropharm.2026.110832","DOIUrl":"10.1016/j.neuropharm.2026.110832","url":null,"abstract":"<div><div>Demyelination caused by oligodendrocyte death is a key contributor to neurological deficits after spinal cord injury (SCI), highlighting the critical need to promote oligodendrocyte precursor cell (OPC) differentiation and remyelination. The transcription factor Olig2 is a master regulator of this process; however, its activation mechanism remains unclear. Given the marked lactate accumulation in post-SCI ischemic microenvironments, we investigated the role of lactate in SCI as well as its regulation on OPC differentiation. In a rat SCI model, it is found that exogenous lactate administration significantly improves motor recovery, preserves neurons and axons, modulates the glial response. Mechanistically, lactate induces histone H3K27 lactylation (H3K27la), which specifically upregulates Olig2 expression, thereby activating OPC differentiation and remyelination. This study uncovers the lactate-H3K27la-Olig2 metabolic-epigenetic axis as a novel endogenous repair mechanism for SCI, providing a foundation for metabolism-targeted therapeutic strategies.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"287 ","pages":"Article 110832"},"PeriodicalIF":4.6,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145960024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the utility of the neurosteroid zuranolone to modify alcohol-related behaviours 评估神经类固醇祖拉诺酮对改变酒精相关行为的效用。
IF 4.6 2区 医学 Q1 NEUROSCIENCES Pub Date : 2026-01-10 DOI: 10.1016/j.neuropharm.2026.110833
Lauren T. Ursich , Amy J. Pearl , Xavier J. Maddern , Andrew J. Lawrence , Leigh C. Walker
Alcohol use is a leading risk factor for premature mortality, yet effective pharmacotherapies remain limited. Neurosteroids, such as allopregnanolone, modulate γ-aminobutyric acid type A (GABAA) receptors and influence alcohol-related behaviours. Zuranolone, an orally bioavailable synthetic analogue of allopregnanolone recently approved for postpartum depression, represents a potential candidate for therapeutic repurposing in alcohol use disorder (AUD). Here, we assessed the effects of acute and daily zuranolone on alcohol-related behaviours in a preclinical binge drinking model, comparing outcomes across sexes and contrasted to the effects of allopregnanolone. Allopregnanolone produced dose-related locomotor responses, characterised by mid dose transient hyperlocomotion and high dose sedation; the mid dose also reduced alcohol intake in both sexes. In contrast, zuranolone produced sex- and dosing schedule-related effects on alcohol consumption: acute high dose administration transiently reduced intake in males in the Latin square design, whereas mid dose administration increased intake under dose escalation in both sexes, particularly in males; however, total intake was unchanged across dosing schedules. Daily zuranolone transiently reduced alcohol intake in males during the first week only. In locomotor assays, acute high dose zuranolone induced sustained hyperactivity in males that was attenuated in females, supporting sex-related differences in sensitivity. Despite its structural similarity to allopregnanolone, zuranolone produced unique behavioural responses, suggesting their pharmacological profiles may differ. Overall, our data do not show robust reductions in alcohol intake following zuranolone administration across dosing schedules in either sex in preclinical models of binge drinking. Future studies are required to explore its potential relevance in comorbid AUD and affective disorders.
饮酒是过早死亡的主要危险因素,但有效的药物治疗仍然有限。神经类固醇,如异孕酮,调节γ-氨基丁酸A型(GABAA)受体并影响酒精相关行为。祖拉诺酮是一种口服合成异孕酮类似物,最近被批准用于产后抑郁症,它代表了酒精使用障碍(AUD)治疗再利用的潜在候选物。在本研究中,我们在临床前狂饮模型中评估了急性和每日使用祖拉诺酮对酒精相关行为的影响,比较了不同性别的结果,并与异孕酮的效果进行了对比。异孕酮产生剂量相关的运动反应,表现为中剂量瞬时运动过度和高剂量镇静;中等剂量也减少了两性的酒精摄入量。相反,祖拉诺酮对饮酒量产生与性别和给药计划相关的影响:拉丁方设计中,急性高剂量给药会短暂减少男性的摄入量,而中剂量给药会在剂量递增的情况下增加两性的摄入量,尤其是男性;然而,总摄入量在给药方案中没有变化。仅在第一周内,每日服用祖拉诺酮可短暂减少男性的酒精摄入量。在运动试验中,急性高剂量祖拉诺酮诱导雄性持续多动,雌性减弱,支持敏感性的性别相关差异。尽管其结构与异孕酮相似,但祖拉诺酮产生了独特的行为反应,表明它们的药理学特征可能不同。总的来说,我们的数据并没有显示在狂饮的临床前模型中,无论男女,在不同的给药方案中服用祖拉诺酮后,酒精摄入量都有明显的减少。未来的研究需要探索其在共病性AUD和情感性障碍中的潜在相关性。
{"title":"Assessing the utility of the neurosteroid zuranolone to modify alcohol-related behaviours","authors":"Lauren T. Ursich ,&nbsp;Amy J. Pearl ,&nbsp;Xavier J. Maddern ,&nbsp;Andrew J. Lawrence ,&nbsp;Leigh C. Walker","doi":"10.1016/j.neuropharm.2026.110833","DOIUrl":"10.1016/j.neuropharm.2026.110833","url":null,"abstract":"<div><div>Alcohol use is a leading risk factor for premature mortality, yet effective pharmacotherapies remain limited. Neurosteroids, such as allopregnanolone, modulate γ-aminobutyric acid type A (GABA<sub>A</sub>) receptors and influence alcohol-related behaviours. Zuranolone, an orally bioavailable synthetic analogue of allopregnanolone recently approved for postpartum depression, represents a potential candidate for therapeutic repurposing in alcohol use disorder (AUD). Here, we assessed the effects of acute and daily zuranolone on alcohol-related behaviours in a preclinical binge drinking model, comparing outcomes across sexes and contrasted to the effects of allopregnanolone. Allopregnanolone produced dose-related locomotor responses, characterised by mid dose transient hyperlocomotion and high dose sedation; the mid dose also reduced alcohol intake in both sexes. In contrast, zuranolone produced sex- and dosing schedule-related effects on alcohol consumption: acute high dose administration transiently reduced intake in males in the Latin square design, whereas mid dose administration increased intake under dose escalation in both sexes, particularly in males; however, total intake was unchanged across dosing schedules. Daily zuranolone transiently reduced alcohol intake in males during the first week only. In locomotor assays, acute high dose zuranolone induced sustained hyperactivity in males that was attenuated in females, supporting sex-related differences in sensitivity. Despite its structural similarity to allopregnanolone, zuranolone produced unique behavioural responses, suggesting their pharmacological profiles may differ. Overall, our data do not show robust reductions in alcohol intake following zuranolone administration across dosing schedules in either sex in preclinical models of binge drinking. Future studies are required to explore its potential relevance in comorbid AUD and affective disorders.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"288 ","pages":"Article 110833"},"PeriodicalIF":4.6,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145952609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brain-penetrant microtubule-stabilizer epothilone B delays isoflurane-induced unconsciousness in mice 脑渗透微管稳定剂艾替隆B延缓异氟醚诱导的小鼠意识缺失。
IF 4.6 2区 医学 Q1 NEUROSCIENCES Pub Date : 2026-01-08 DOI: 10.1016/j.neuropharm.2026.110834
Yixiang Huang , Zitong Qiu , Xinyue Yu, Sophia Lee, Xiran Zeng, Abbie Chang, Michael C. Wiest
Inhalational anesthetics are currently believed to cause unconsciousness by acting on multiple molecular targets including neural ion channels, receptors, mitochondria, synaptic proteins, and cytoskeletal proteins. Inhalational anesthetics including isoflurane bind to cytoskeletal microtubules (MTs), potentially contributing to causing unconsciousness. This possibility is supported by our demonstration of isoflurane resistance in rats treated once with the brain-penetrant MT-stabilizing drug epothilone B (epoB), and by a recent study in mice using a similar drug given daily over two weeks, which found increased sensitivity to isoflurane. To further characterize the contribution of MTs as functionally relevant targets of volatile anesthetics in mice, we measured latencies to loss of righting reflex (LORR) under isoflurane in mice injected once subcutaneously with vehicle or epoB.
We found significantly increased LORR latencies (i.e., anesthetic resistance) in 8 mg/kg epoB-treated mice on the day following injection, with reduced effects on subsequent days. The 29-s within-subject increase in LORR latencies is not large compared to the variability among different animals, but it represents a statistically large within-subject effect as represented by a Cohen's d of 0.8. The effect could not be accounted for by tolerance from repeated exposure to isoflurane. Our results support that binding of the inhalational anesthetic isoflurane to MTs contributes to LORR in mice, as it does in rats. Our findings support the Orchestrated Objective Reduction (Orch OR) model that posits consciousness as a property of a quantum physical state of neural MTs. We also discuss possible sex differences in anesthetic mechanisms suggested by our data.
目前认为,吸入麻醉剂通过作用于多种分子靶点,包括神经离子通道、受体、线粒体、突触蛋白和细胞骨架蛋白,导致无意识。包括异氟醚在内的吸入麻醉剂与细胞骨架微管(MTs)结合,可能导致无意识。这种可能性得到了我们的证明,即大鼠对异氟烷产生了耐药性,这些大鼠曾接受过一次脑渗透性mt稳定药物epothilone B (epoB)的治疗,而最近的一项研究发现,每天服用类似药物的小鼠在两周内对异氟烷的敏感性增加。为了进一步表征MTs作为挥发性麻醉药在小鼠中的功能相关靶点的作用,我们测量了异氟醚对小鼠的转直反射(LORR)丧失的潜伏期,这些小鼠皮下注射一次载药或epoB。我们发现8 mg/kg epob处理的小鼠在注射后一天的LORR潜伏期(即麻醉抗性)显著增加,随后几天的影响减弱。与不同动物之间的可变性相比,29秒内LORR潜伏期的增加并不大,但它代表了统计学上较大的被试内效应,用Cohen's d = 0.8表示。这种影响不能用反复接触异氟醚的耐受性来解释。我们的研究结果支持吸入麻醉剂异氟醚与MTs的结合有助于小鼠的LORR,正如它在大鼠中的作用一样。我们的研究结果支持了“协调客观还原”(Orch OR)模型,该模型认为意识是神经mt量子物理状态的一种属性。我们还讨论了数据所提示的麻醉机制中可能存在的性别差异。
{"title":"Brain-penetrant microtubule-stabilizer epothilone B delays isoflurane-induced unconsciousness in mice","authors":"Yixiang Huang ,&nbsp;Zitong Qiu ,&nbsp;Xinyue Yu,&nbsp;Sophia Lee,&nbsp;Xiran Zeng,&nbsp;Abbie Chang,&nbsp;Michael C. Wiest","doi":"10.1016/j.neuropharm.2026.110834","DOIUrl":"10.1016/j.neuropharm.2026.110834","url":null,"abstract":"<div><div>Inhalational anesthetics are currently believed to cause unconsciousness by acting on multiple molecular targets including neural ion channels, receptors, mitochondria, synaptic proteins, and cytoskeletal proteins. Inhalational anesthetics including isoflurane bind to cytoskeletal microtubules (MTs), potentially contributing to causing unconsciousness. This possibility is supported by our demonstration of isoflurane resistance in rats treated once with the brain-penetrant MT-stabilizing drug epothilone B (epoB), and by a recent study in mice using a similar drug given daily over two weeks, which found <em>increased</em> sensitivity to isoflurane. To further characterize the contribution of MTs as functionally relevant targets of volatile anesthetics in mice, we measured latencies to loss of righting reflex (LORR) under isoflurane in mice injected once subcutaneously with vehicle or epoB.</div><div>We found significantly increased LORR latencies (i.e., anesthetic resistance) in 8 mg/kg epoB-treated mice on the day following injection, with reduced effects on subsequent days. The 29-s within-subject increase in LORR latencies is not large compared to the variability among different animals, but it represents a statistically large within-subject effect as represented by a Cohen's d of 0.8. The effect could not be accounted for by tolerance from repeated exposure to isoflurane. Our results support that binding of the inhalational anesthetic isoflurane to MTs contributes to LORR in mice, as it does in rats. Our findings support the Orchestrated Objective Reduction (Orch OR) model that posits consciousness as a property of a quantum physical state of neural MTs. We also discuss possible sex differences in anesthetic mechanisms suggested by our data.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"287 ","pages":"Article 110834"},"PeriodicalIF":4.6,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145948989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acetazolamide alleviates motion sickness by inhibiting inner ear carbonic anhydrase 2 and reducing endolymph volume 乙酰唑胺通过抑制内耳碳酸酐酶2和减少内淋巴体积减轻晕动病
IF 4.6 2区 医学 Q1 NEUROSCIENCES Pub Date : 2026-01-07 DOI: 10.1016/j.neuropharm.2026.110829
Miao-Miao Chen , Chao-Yue Tian , Jian-Gang Ge , Xia Li , Bin Peng , Wei Ji , Lei Cui , Li-Hua Xu , Zheng-Lin Jiang
Motion sickness is common in aerospace, aviation and maritime operations, and travel by vehicles or ships. Existing preventive and therapeutic drugs for motion sickness induce central nervous system (CNS)-related side effects; therefore, there is an urgent need to find new anti-motion sickness targets and to develop novel drugs with reduced adverse effects. In this study, we found that rotational stimulation significantly upregulated carbonic anhydrase 2 (CA2) expression in the inner ears of guinea pigs and mice. Pretreatment with acetazolamide (AZ), an inhibitor of carbonic anhydrase, effectively mitigated motion sickness-related behavioral symptoms in both species and inhibited increase in the inner ear endolymph volume induced by rotational stimulation. Further investigations revealed that AZ mediated its anti-motion sickness effects primarily through mechanisms involving the reduction of intracellular H+ concentrations in vestibular epithelial cells, inhibition of Na+-K+-ATPase activity, and modulation of intracellular Na+ and K+ homeostasis, thereby attenuating endolymph accumulation in the inner ear. This study demonstrated for the first time an involvement of the inner ear CA2 in the induction of motion sickness and an anti-motion sickness effect of its inhibitor AZ, providing a new strategy for developing anti-motion sickness drugs acting on the inner ear.
晕动病在航天、航空和海上作业以及乘坐车辆或船只旅行中很常见。现有的预防和治疗晕车的药物会引起中枢神经系统(CNS)相关副作用;因此,迫切需要寻找新的抗晕动病靶点,开发副作用较小的新药。在这项研究中,我们发现旋转刺激显著上调豚鼠和小鼠内耳中的碳酸酐酶2 (CA2)表达。乙酰唑胺(acetazolamide, AZ)是一种碳酸酐酶抑制剂,可以有效缓解两种动物的晕动病相关行为症状,并抑制旋转刺激引起的内耳内淋巴体积增加。进一步的研究表明,阿兹兰抗晕动病的作用机制主要包括降低前庭上皮细胞内H+浓度,抑制Na+-K+- atp酶活性,调节细胞内Na+和K+稳态,从而减轻内耳淋巴积聚。本研究首次证实了内耳CA2参与晕动病的诱导及其抑制剂AZ的抗晕动病作用,为开发内耳抗晕动病药物提供了新的策略。
{"title":"Acetazolamide alleviates motion sickness by inhibiting inner ear carbonic anhydrase 2 and reducing endolymph volume","authors":"Miao-Miao Chen ,&nbsp;Chao-Yue Tian ,&nbsp;Jian-Gang Ge ,&nbsp;Xia Li ,&nbsp;Bin Peng ,&nbsp;Wei Ji ,&nbsp;Lei Cui ,&nbsp;Li-Hua Xu ,&nbsp;Zheng-Lin Jiang","doi":"10.1016/j.neuropharm.2026.110829","DOIUrl":"10.1016/j.neuropharm.2026.110829","url":null,"abstract":"<div><div>Motion sickness is common in aerospace, aviation and maritime operations, and travel by vehicles or ships. Existing preventive and therapeutic drugs for motion sickness induce central nervous system (CNS)-related side effects; therefore, there is an urgent need to find new anti-motion sickness targets and to develop novel drugs with reduced adverse effects. In this study, we found that rotational stimulation significantly upregulated carbonic anhydrase 2 (CA2) expression in the inner ears of guinea pigs and mice. Pretreatment with acetazolamide (AZ), an inhibitor of carbonic anhydrase, effectively mitigated motion sickness-related behavioral symptoms in both species and inhibited increase in the inner ear endolymph volume induced by rotational stimulation. Further investigations revealed that AZ mediated its anti-motion sickness effects primarily through mechanisms involving the reduction of intracellular H<sup>+</sup> concentrations in vestibular epithelial cells, inhibition of Na<sup>+</sup>-K<sup>+</sup>-ATPase activity, and modulation of intracellular Na<sup>+</sup> and K<sup>+</sup> homeostasis, thereby attenuating endolymph accumulation in the inner ear. This study demonstrated for the first time an involvement of the inner ear CA2 in the induction of motion sickness and an anti-motion sickness effect of its inhibitor AZ, providing a new strategy for developing anti-motion sickness drugs acting on the inner ear.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"287 ","pages":"Article 110829"},"PeriodicalIF":4.6,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145940484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NLRP10 ablation alleviates neuropathic pain by inhibiting excessive NIX/LC3-dependent mitophagy in the spinal cord NLRP10消融通过抑制脊髓过度的NIX/ lc3依赖性有丝分裂来减轻神经性疼痛。
IF 4.6 2区 医学 Q1 NEUROSCIENCES Pub Date : 2026-01-06 DOI: 10.1016/j.neuropharm.2026.110831
Xiaoyu Zhang, Jiale Sun, Fengtian Zhao, Ting Liu, Shangchen Yu, Wen Zhang, Xuebi Tian

Objective

Neuropathic pain (NP) presents a significant clinical challenge due to its physical and psychological impact and the lack of effective treatments. While the pathogenesis of NP remains incompletely understood, emerging evidence suggests that Nod-like receptor pyrin domain-containing protein 10 (NLRP10) participates in neurological disorders via neuroinflammation and mitochondrial autophagy. This study investigates roles of NLRP10 in NP pathogenesis and elucidates its mechanism in triggering neuroinflammation-mediated NIX/LC3-dependent mitochondrial dysfunction.

Methods

A spared nerve injury (SNI) mouse model was established to investigate neuropathic pain (NP) mechanisms. Pain behaviors were assessed using the mechanical pain withdrawal threshold (MPWT). Adeno-associated virus (AAV) was administered to the spinal dorsal horn (SDH) to downregulate NLRP10 or overexpress NIX. Neuroinflammatory responses and alterations in mitophagy were subsequently evaluated using Western blotting, ELISA, immunofluorescence, and transmission electron microscopy.

Results

SNI mice exhibited upregulated NLRP10 inflammasome expression and enhanced activation of the downstream NLRP12/ASC/Caspase1 pathway in the SDH. This was accompanied by significant increases in NIX/LC3 protein concentrations and decreased mitochondrial-related protein levels after surgery. NLRP10 predominantly colocalized with neuronal marker NeuN in SDH. Transmission electron microscopy revealed characteristic mitochondrial damage. Knockdown of NLRP10 with mNLRP10 effectively suppressed inflammatory activation, attenuated excessive mitochondrial autophagy, and alleviated NP manifestations. Notably, NIX overexpression abolished the protective effects of NLRP10 reduction in SNI mice.

Conclusion

In summary, our findings demonstrate that NLRP10 downregulation inhibit NLRP12/ASC/Caspase1 pathway activation and prevents pathological mitochondrial autophagy, ultimately alleviating NP. These results identify NLRP10 as a promising therapeutic target for NP management.
目的:神经性疼痛(NP)由于其对身体和心理的影响以及缺乏有效的治疗方法,给临床带来了重大挑战。虽然NP的发病机制尚不完全清楚,但新出现的证据表明,nod样受体pyrin结构域蛋白10 (NLRP10)通过神经炎症和线粒体自噬参与神经系统疾病。本研究探讨了NLRP10在NP发病机制中的作用,并阐明了其引发神经炎症介导的NIX/ lc3依赖性线粒体功能障碍的机制。方法:建立神经损伤(SNI)小鼠模型,探讨神经性疼痛(NP)的机制。采用机械疼痛戒断阈值(MPWT)评估疼痛行为。将腺相关病毒(AAV)注入脊髓背角(SDH),下调NLRP10或过表达NIX。随后使用Western blotting、ELISA、免疫荧光和透射电镜评估神经炎症反应和线粒体自噬的改变。结果:SNI小鼠在SDH中NLRP10炎性小体表达上调,下游NLRP12/ASC/Caspase1通路激活增强。这伴随着手术后NIX/LC3蛋白浓度的显著增加和线粒体相关蛋白水平的降低。NLRP10在SDH中主要与神经元标记物NeuN共定位。透射电镜显示特征性线粒体损伤。用mNLRP10敲低NLRP10可有效抑制炎症激活,减轻线粒体过度自噬,减轻NP表现。值得注意的是,NIX过表达消除了SNI小鼠NLRP10减少的保护作用。结论:综上所述,我们的研究结果表明,NLRP10下调可抑制NLRP12/ASC/Caspase1通路的激活,阻止病理性线粒体自噬,最终缓解NP。这些结果确定NLRP10是NP治疗的有希望的治疗靶点。
{"title":"NLRP10 ablation alleviates neuropathic pain by inhibiting excessive NIX/LC3-dependent mitophagy in the spinal cord","authors":"Xiaoyu Zhang,&nbsp;Jiale Sun,&nbsp;Fengtian Zhao,&nbsp;Ting Liu,&nbsp;Shangchen Yu,&nbsp;Wen Zhang,&nbsp;Xuebi Tian","doi":"10.1016/j.neuropharm.2026.110831","DOIUrl":"10.1016/j.neuropharm.2026.110831","url":null,"abstract":"<div><h3>Objective</h3><div>Neuropathic pain (NP) presents a significant clinical challenge due to its physical and psychological impact and the lack of effective treatments. While the pathogenesis of NP remains incompletely understood, emerging evidence suggests that Nod-like receptor pyrin domain-containing protein 10 (NLRP10) participates in neurological disorders via neuroinflammation and mitochondrial autophagy. This study investigates roles of NLRP10 in NP pathogenesis and elucidates its mechanism in triggering neuroinflammation-mediated NIX/LC3-dependent mitochondrial dysfunction.</div></div><div><h3>Methods</h3><div>A spared nerve injury (SNI) mouse model was established to investigate neuropathic pain (NP) mechanisms. Pain behaviors were assessed using the mechanical pain withdrawal threshold (MPWT). Adeno-associated virus (AAV) was administered to the spinal dorsal horn (SDH) to downregulate NLRP10 or overexpress NIX. Neuroinflammatory responses and alterations in mitophagy were subsequently evaluated using Western blotting, ELISA, immunofluorescence, and transmission electron microscopy.</div></div><div><h3>Results</h3><div>SNI mice exhibited upregulated NLRP10 inflammasome expression and enhanced activation of the downstream NLRP12/ASC/Caspase1 pathway in the SDH. This was accompanied by significant increases in NIX/LC3 protein concentrations and decreased mitochondrial-related protein levels after surgery. NLRP10 predominantly colocalized with neuronal marker NeuN in SDH. Transmission electron microscopy revealed characteristic mitochondrial damage. Knockdown of NLRP10 with mNLRP10 effectively suppressed inflammatory activation, attenuated excessive mitochondrial autophagy, and alleviated NP manifestations. Notably, NIX overexpression abolished the protective effects of NLRP10 reduction in SNI mice.</div></div><div><h3>Conclusion</h3><div>In summary, our findings demonstrate that NLRP10 downregulation inhibit NLRP12/ASC/Caspase1 pathway activation and prevents pathological mitochondrial autophagy, ultimately alleviating NP. These results identify NLRP10 as a promising therapeutic target for NP management.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"287 ","pages":"Article 110831"},"PeriodicalIF":4.6,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145934083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peripheral alpha-2 antagonist vatinoxan improves dexmedetomidine-induced perivascular cerebrospinal fluid flow without affecting electroencephalogram activity in female rats 外周α -2拮抗剂vatinoxan改善右美托咪定诱导的血管周围脑脊液流动,而不影响雌性大鼠的脑电图活动。
IF 4.6 2区 医学 Q1 NEUROSCIENCES Pub Date : 2026-01-02 DOI: 10.1016/j.neuropharm.2026.110828
Hanna Antila , Sonja C. Jalonen , Niklas Daniel Åke Persson , Martta Peltoniemi , Terhi J. Lohela , Tuomas O. Lilius

Background

The glymphatic concept represents a brain-wide perivascular fluid network contributing to brain metabolite clearance. Dexmedetomidine, a sedative α2-adrenergic receptor agonist, enhances perivascular cerebrospinal fluid (CSF) flow by reducing central noradrenergic tone and inducing sleep-like electroencephalogram (EEG) slow-wave activity. Concurrently, α2-adrenergic agonists modulate peripheral physiological functions, possibly influencing the central glymphatic dynamics. Utilizing peripherally restricted α2-adrenergic antagonist vatinoxan, we evaluated the role of physiological parameters on the glymphatic-enhancing properties of dexmedetomidine.

Methods

The effects of vatinoxan on the EEG spectral signature of dexmedetomidine and physiological parameters were investigated in female Sprague-Dawley rats. The whole-body distribution of intracisternally infused radiolabeled CSF tracer technetium-99m-labeled diethylenetriaminepentaacetic acid ([99ᵐTc]Tc-DTPA) was quantified utilizing single-photon emission computed tomography (SPECT).

Results

While vatinoxan had no influence on the EEG spectral signature of dexmedetomidine sedation, it alleviated the peripheral effects, such as peripheral vasoconstriction, hyperglycemia, diuresis, and hyperosmolality. Vatinoxan created a unique CSF tracer distribution pattern by elevating the cortical tracer availability, quantified as area under the time–activity curve (AUC0-91), by 36 % (AUC0–91 ratio, 1.36; 95 % CI, 1.0–1.8), increasing the maximum tracer concentration (Cmax) in the intracranial space by 39 % (Cmax ratio, 1.39; 95 % CI, 1.06–1.81), and decreasing the tracer availability in the spinal canal by 25 % (AUC0–91 ratio, 0.75; 95 % CI, 0.66–0.85). Simultaneously, vatinoxan promoted the tracer egress from the CNS by 360 % (AUC0–91 ratio, 4.6; 95 % CI, 2.7–7.8).

Conclusions

Antagonism of peripheral α2-adrenergic receptors with vatinoxan during dexmedetomidine sedation enhances perivascular CSF influx, irrespective of slow-wave activity.
背景:类淋巴的概念代表了一个全脑范围的血管周围流体网络,有助于脑代谢物的清除。右美托咪定是一种镇静的α2-肾上腺素能受体激动剂,通过降低中枢去甲肾上腺素能张力和诱导睡眠样脑电图(EEG)慢波活动来增强血管周围脑脊液(CSF)的流动。同时,α2-肾上腺素能激动剂调节外周生理功能,可能影响中枢淋巴动力学。利用外周限制性α2-肾上腺素能拮抗剂瓦替诺坦,我们评估了生理参数对右美托咪定淋巴增强特性的作用。方法:观察瓦替诺散对雌性Sprague-Dawley大鼠右美托咪定脑电图特征及生理参数的影响。利用单光子发射计算机断层扫描(SPECT)定量观察脑内灌注放射性标记脑脊液示踪剂锝-99m标记二乙烯三胺五乙酸([99 Tc]Tc- dtpa)的全身分布。结果:瓦替诺散对右美托咪定镇静的脑电图频谱特征无影响,但可减轻外周血管收缩、高血糖、利尿、高渗等外周效应。Vatinoxan通过将皮质示踪剂可用性(量化为时间-活性曲线下面积(AUC0-91))提高36% (AUC0-91比值,1.36;95% CI, 1.0-1.8),将颅内间隙最大示踪剂浓度(Cmax)提高39% (Cmax比值,1.39;95% CI, 1.06-1.81),并将椎管内示踪剂可用性降低25% (AUC0-91比值,0.75;95% CI, 0.66-0.85),创造了独特的脑脊液示踪剂分布模式。同时,vatinoxan促进了360%的示踪剂从中枢神经系统的输出(AUC0-91比值,4.6;95% CI, 2.7-7.8)。结论:在右美托咪定镇静期间,伐他诺坦对外周α2-肾上腺素能受体的拮抗作用增强了血管周围脑脊液内流,而与慢波活性无关。
{"title":"Peripheral alpha-2 antagonist vatinoxan improves dexmedetomidine-induced perivascular cerebrospinal fluid flow without affecting electroencephalogram activity in female rats","authors":"Hanna Antila ,&nbsp;Sonja C. Jalonen ,&nbsp;Niklas Daniel Åke Persson ,&nbsp;Martta Peltoniemi ,&nbsp;Terhi J. Lohela ,&nbsp;Tuomas O. Lilius","doi":"10.1016/j.neuropharm.2026.110828","DOIUrl":"10.1016/j.neuropharm.2026.110828","url":null,"abstract":"<div><h3>Background</h3><div>The glymphatic concept represents a brain-wide perivascular fluid network contributing to brain metabolite clearance. Dexmedetomidine, a sedative α<sub>2</sub>-adrenergic receptor agonist, enhances perivascular cerebrospinal fluid (CSF) flow by reducing central noradrenergic tone and inducing sleep-like electroencephalogram (EEG) slow-wave activity. Concurrently, α<sub>2</sub>-adrenergic agonists modulate peripheral physiological functions, possibly influencing the central glymphatic dynamics. Utilizing peripherally restricted α<sub>2</sub>-adrenergic antagonist vatinoxan, we evaluated the role of physiological parameters on the glymphatic-enhancing properties of dexmedetomidine.</div></div><div><h3>Methods</h3><div>The effects of vatinoxan on the EEG spectral signature of dexmedetomidine and physiological parameters were investigated in female Sprague-Dawley rats. The whole-body distribution of intracisternally infused radiolabeled CSF tracer technetium-99m-labeled diethylenetriaminepentaacetic acid ([<sup>99</sup>ᵐTc]Tc-DTPA) was quantified utilizing single-photon emission computed tomography (SPECT).</div></div><div><h3>Results</h3><div>While vatinoxan had no influence on the EEG spectral signature of dexmedetomidine sedation, it alleviated the peripheral effects, such as peripheral vasoconstriction, hyperglycemia, diuresis, and hyperosmolality. Vatinoxan created a unique CSF tracer distribution pattern by elevating the cortical tracer availability, quantified as area under the time–activity curve (AUC<sub>0-91</sub>), by 36 % (AUC<sub>0–91</sub> ratio, 1.36; 95 % CI, 1.0–1.8), increasing the maximum tracer concentration (C<sub>max</sub>) in the intracranial space by 39 % (C<sub>max</sub> ratio, 1.39; 95 % CI, 1.06–1.81), and decreasing the tracer availability in the spinal canal by 25 % (AUC<sub>0–91</sub> ratio, 0.75; 95 % CI, 0.66–0.85). Simultaneously, vatinoxan promoted the tracer egress from the CNS by 360 % (AUC<sub>0–91</sub> ratio, 4.6; 95 % CI, 2.7–7.8).</div></div><div><h3>Conclusions</h3><div>Antagonism of peripheral α<sub>2</sub>-adrenergic receptors with vatinoxan during dexmedetomidine sedation enhances perivascular CSF influx, irrespective of slow-wave activity.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"287 ","pages":"Article 110828"},"PeriodicalIF":4.6,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nose-to-brain delivery of dopamine to the striatum of rats using neurotransmitter-loaded solid lipid nanoparticles: an in vivo study by brain microdialysis 使用装载神经递质固体脂质纳米颗粒将多巴胺经鼻至脑输送到大鼠纹状体:一项脑微透析的体内研究
IF 4.6 2区 医学 Q1 NEUROSCIENCES Pub Date : 2026-01-02 DOI: 10.1016/j.neuropharm.2026.110830
Laura Dazzi , Giuseppe Talani , Giuseppe Trapani , Luigi Capasso , Annalucia Carbone , Sante Di Gioia , Massimo Conese , Adriana Trapani , Enrico Sanna
The intranasal route is a noninvasive method of delivering therapeutic compounds to the Central Nervous System (CNS). However, challenges associated with this method include reduced drug absorption, limited administered volume, insufficient nasal permeability, and enzymatic nasal metabolism. Nanotechnology-based delivery systems are being developed to overcome these limitations and improve drug availability and therapeutic effectiveness. In this regard, we recently developed dopamine (DA)-loaded solid lipid nanoparticles (DA-SLNs) using self-emulsifying Gelucire® 50/13 to form PEGylated SLNs for intranasal administration. To enhance mucoadhesion, we coated these lipid nanoparticles with the mucoadhesive cationic polymer glycolchitosan (GCS). In the present study, we performed microdialysis and electrophysiological experiments in a male rat model to evaluate the ability of GCS-DA-SLNs, when administered intranasally, to modify striatal extracellular DA concentrations and induce changes in the functional properties of striatal neurons. The results showed that intranasal administration of GCS-DA-SLNs at DA doses of 2.5 and 4 mg/kg significantly increased the extracellular concentration of DA (+130 ± 38 %) and the extracellular concentration of DOPAC (only at the lower dose of 1 mg/kg, by 70 ± 3 %). Ex vivo electrophysiological recordings in striatal neurons revealed that intranasal administration of GCS-DA-SLNs, at a DA dose of 4 mg/kg, but not 2.5, mg/kg, enhanced HCN-mediated Ih current amplitude. A similar effect was also observed in vitro when striatal neurons were exposed to DA or the D1 receptor agonist SKF81297. Overall, our data underscore the significant potential of using GCS-DA-SLN nanocarriers to efficiently deliver DA and other therapeutic compounds via the nose-to-brain pathway.
鼻内途径是一种将治疗性化合物输送到中枢神经系统(CNS)的非侵入性方法。然而,与该方法相关的挑战包括药物吸收减少、给药量有限、鼻渗透性不足和酶促鼻代谢。人们正在开发基于纳米技术的递送系统,以克服这些限制,提高药物的可用性和治疗效果。在这方面,我们最近开发了多巴胺(DA)负载的固体脂质纳米颗粒(DA- sln),使用自乳化Gelucire®50/13形成聚乙二醇化的sln用于鼻内给药。为了增强粘着性,我们用粘着阳离子聚合物糖聚糖(GCS)包覆了这些脂质纳米颗粒。在本研究中,我们在雄性大鼠模型中进行了微透析和电生理实验,以评估经鼻给药gcs -DA- sln改变纹状体细胞外DA浓度和诱导纹状体神经元功能特性变化的能力。结果表明,经鼻给药剂量为2.5和4 mg/kg的gcs -DA- sln显著增加DA细胞外浓度(+130±38%)和DOPAC细胞外浓度(仅在较低剂量为1 mg/kg时,增加70±3%)。纹状体神经元的离体电生理记录显示,以4 mg/kg(而非2.5 mg/kg)的DA剂量鼻内给药GCS-DA-SLNs可增强hcn介导的Ih电流振幅。当纹状体神经元暴露于DA或D1受体激动剂SKF81297时,在体外也观察到类似的效果。总的来说,我们的数据强调了使用GCS-DA-SLN纳米载体通过鼻到脑途径有效递送DA和其他治疗性化合物的巨大潜力。
{"title":"Nose-to-brain delivery of dopamine to the striatum of rats using neurotransmitter-loaded solid lipid nanoparticles: an in vivo study by brain microdialysis","authors":"Laura Dazzi ,&nbsp;Giuseppe Talani ,&nbsp;Giuseppe Trapani ,&nbsp;Luigi Capasso ,&nbsp;Annalucia Carbone ,&nbsp;Sante Di Gioia ,&nbsp;Massimo Conese ,&nbsp;Adriana Trapani ,&nbsp;Enrico Sanna","doi":"10.1016/j.neuropharm.2026.110830","DOIUrl":"10.1016/j.neuropharm.2026.110830","url":null,"abstract":"<div><div>The intranasal route is a noninvasive method of delivering therapeutic compounds to the Central Nervous System (CNS). However, challenges associated with this method include reduced drug absorption, limited administered volume, insufficient nasal permeability, and enzymatic nasal metabolism. Nanotechnology-based delivery systems are being developed to overcome these limitations and improve drug availability and therapeutic effectiveness. In this regard, we recently developed dopamine (DA)-loaded solid lipid nanoparticles (DA-SLNs) using self-emulsifying Gelucire® 50/13 to form PEGylated SLNs for intranasal administration. To enhance mucoadhesion, we coated these lipid nanoparticles with the mucoadhesive cationic polymer glycolchitosan (GCS). In the present study, we performed microdialysis and electrophysiological experiments in a male rat model to evaluate the ability of GCS-DA-SLNs, when administered intranasally, to modify striatal extracellular DA concentrations and induce changes in the functional properties of striatal neurons. The results showed that intranasal administration of GCS-DA-SLNs at DA doses of 2.5 and 4 mg/kg significantly increased the extracellular concentration of DA (+130 ± 38 %) and the extracellular concentration of DOPAC (only at the lower dose of 1 mg/kg, by 70 ± 3 %). Ex vivo electrophysiological recordings in striatal neurons revealed that intranasal administration of GCS-DA-SLNs, at a DA dose of 4 mg/kg, but not 2.5, mg/kg, enhanced HCN-mediated <em>I</em><sub>h</sub> current amplitude. A similar effect was also observed <em>in vitro</em> when striatal neurons were exposed to DA or the D1 receptor agonist SKF81297. Overall, our data underscore the significant potential of using GCS-DA-SLN nanocarriers to efficiently deliver DA and other therapeutic compounds via the nose-to-brain pathway.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"287 ","pages":"Article 110830"},"PeriodicalIF":4.6,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145891195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spinal Shati/nat8l regulates mechanical hyperalgesia through NAAG-mGluR3 signaling in neuropathic pain 脊髓沙/ nat81通过NAAG-mGluR3信号调控神经性疼痛的机械性痛觉过敏。
IF 4.6 2区 医学 Q1 NEUROSCIENCES Pub Date : 2025-12-31 DOI: 10.1016/j.neuropharm.2025.110819
Keisuke Miyamoto , Kousuke Tatsuta , Kazuyuki Sumi , Kyosuke Uno , Kazuki Tokoro , Shin-ichi Muramatsu , Naotaka Izuo , Kazuhiko Kume , Atsumi Nitta , Masahiro Ohsawa
Shati/nat8l catalyzes the synthesis of N-acetylaspartate (NAA), a precursor for N-acetylaspartylglutamate (NAAG), an endogenous agonist of group II metabotropic glutamate receptor 3 (mGluR3). Although spinal mGluR3 is known to modulate nociceptive signaling, the functional role of Shati/nat8l in pain transmission has remained unclear. In this study, we investigated the involvement of spinal Shati/nat8l in mechanical nociceptive processing and neuropathic pain.
We found that Shati/nat8l knockout (Shati−/−) mice exhibited a significantly decreased mechanical pain threshold compared to wild-type controls. This hypersensitivity was reversed by adeno-associated virus (AAV)-mediated expression of Shati/nat8l in the spinal dorsal horn. Intrathecal administration of NAAG—but not NAA—restored mechanical thresholds in Shati−/− mice, and this effect was blocked by the group II mGluR antagonist LY341495. In addition, treatment with LY341495 showed antinociceptive effect in normal mice at higher doses. In a peripheral nerve injury model, expression of Shati/nat8l mRNA in the ipsilateral dorsal horn was significantly decreased. Importantly, AAV-mediated restoration of Shati/nat8l expression in the dorsal horn alleviated neuropathic mechanical hyperalgesia and normalized Shati/nat8l mRNA levels.
These findings suggest that downregulation of spinal Shati/nat8l contributes to mechanical hypersensitivity by impairing the NAAG-mGluR3 signaling pathway. Targeting the Shati/nat8l–NAAG–mGluR3 axis may offer a novel therapeutic strategy for the treatment of neuropathic pain.
Shati/nat8l可催化n -乙酰天冬氨酸(NAA)的合成,NAA是n -乙酰天冬氨酸谷氨酸(NAAG)的前体,NAAG是II组代谢型谷氨酸受体3 (mGluR3)的内源性激动剂。虽然已知脊髓mGluR3可以调节伤害性信号,但Shati/ nat81在疼痛传递中的功能作用仍不清楚。在这项研究中,我们研究了脊髓沙/ nat81在机械性伤害知觉加工和神经性疼痛中的参与。我们发现,与野生型对照相比,Shati/nat8l基因敲除(Shati-/-)小鼠的机械痛阈值显著降低。这种超敏反应被腺相关病毒(AAV)介导的脊髓背角Shati/ nat81的表达逆转。鞘内给药naag(而非naag)恢复了Shati-/-小鼠的机械阈值,这种作用被II组mGluR拮抗剂LY341495阻断。此外,LY341495在高剂量下对正常小鼠具有抗伤害感受性作用。在周围神经损伤模型中,同侧背角Shati/ nat81mrna的表达明显降低。重要的是,aav介导的背角Shati/nat8l表达的恢复减轻了神经性机械性痛觉过敏,并使Shati/nat8l mRNA水平正常化。这些发现表明,脊柱Shati/nat8l的下调通过损害NAAG-mGluR3信号通路参与机械超敏反应。靶向Shati/nat8l-NAAG-mGluR3轴可能为神经性疼痛的治疗提供一种新的治疗策略。
{"title":"Spinal Shati/nat8l regulates mechanical hyperalgesia through NAAG-mGluR3 signaling in neuropathic pain","authors":"Keisuke Miyamoto ,&nbsp;Kousuke Tatsuta ,&nbsp;Kazuyuki Sumi ,&nbsp;Kyosuke Uno ,&nbsp;Kazuki Tokoro ,&nbsp;Shin-ichi Muramatsu ,&nbsp;Naotaka Izuo ,&nbsp;Kazuhiko Kume ,&nbsp;Atsumi Nitta ,&nbsp;Masahiro Ohsawa","doi":"10.1016/j.neuropharm.2025.110819","DOIUrl":"10.1016/j.neuropharm.2025.110819","url":null,"abstract":"<div><div><em>Shati/nat8l</em> catalyzes the synthesis of N-acetylaspartate (NAA), a precursor for N-acetylaspartylglutamate (NAAG), an endogenous agonist of group II metabotropic glutamate receptor 3 (mGluR3). Although spinal mGluR3 is known to modulate nociceptive signaling, the functional role of <em>Shati/nat8l</em> in pain transmission has remained unclear. In this study, we investigated the involvement of spinal <em>Shati/nat8l</em> in mechanical nociceptive processing and neuropathic pain.</div><div>We found that <em>Shati/nat8l</em> knockout (Shati−/−) mice exhibited a significantly decreased mechanical pain threshold compared to wild-type controls. This hypersensitivity was reversed by adeno-associated virus (AAV)-mediated expression of <em>Shati/nat8l</em> in the spinal dorsal horn. Intrathecal administration of NAAG—but not NAA—restored mechanical thresholds in Shati−/− mice, and this effect was blocked by the group II mGluR antagonist LY341495. In addition, treatment with LY341495 showed antinociceptive effect in normal mice at higher doses. In a peripheral nerve injury model, expression of <em>Shati/nat8l</em> mRNA in the ipsilateral dorsal horn was significantly decreased. Importantly, AAV-mediated restoration of <em>Shati/nat8l</em> expression in the dorsal horn alleviated neuropathic mechanical hyperalgesia and normalized <em>Shati/nat8l</em> mRNA levels.</div><div>These findings suggest that downregulation of spinal <em>Shati/nat8l</em> contributes to mechanical hypersensitivity by impairing the NAAG-mGluR3 signaling pathway. Targeting the <em>Shati/nat8l</em>–NAAG–mGluR3 axis may offer a novel therapeutic strategy for the treatment of neuropathic pain.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"287 ","pages":"Article 110819"},"PeriodicalIF":4.6,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145892969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Neuropharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1